Gentronix and Apredica to create predictive-toxicology service
Gentronix, a genotoxicity product and services provider in Manchester, UK, and US-based Apredica, an ADME-Tox contract research laboratory, are to collaborate on drug-discovery support services focusing on predictive toxicology. The aim is to reduce the failure rate of drugs in late development, particularly due to toxicity, thereby improving the efficiency of drug discovery and increasing assurance that new drugs are safe.
Gentronix, a genotoxicity product and services provider in Manchester, UK, and US-based Apredica, an ADME-Tox contract research laboratory, are to collaborate on drug-discovery support services focusing on predictive toxicology. The aim is to reduce the failure rate of drugs in late development, particularly due to toxicity, thereby improving the efficiency of drug discovery and increasing assurance that new drugs are safe.
In addition to the joint service offering, the two companies will become mutual agents.
The alliance offers a new suite of predictive in vitro toxicology services to help improve the speed and efficiency of drug development.
John Nicholson, chairman and ceo of Gentronix said: "Early prediction of genotoxicity and attrition-rate improvement is critical to the success of drug discovery. Our alliance with Apredica allows our customers to concentrate resources on compounds most likely to succeed in development, and to select the best candidates for clinical trials sooner."